An in-vitro model for tumor immunotherapy with antibody heteroconjugates
- 31 December 1988
- journal article
- review article
- Published by Elsevier in Immunology Today
- Vol. 9 (9) , 257-260
- https://doi.org/10.1016/0167-5699(88)91304-7
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Amplification of the immune response by agonistic antibodiesImmunology Today, 1986
- T cell activation by anti‐T3 antibodies: Comparison of IgG1 and IgG2b switch variants and direct evidence for accessory function of macrophage Fc receptorsEuropean Journal of Immunology, 1986
- Specific targeting of human peripheral blood T cells by heteroaggregates containing anti-T3 crosslinked to anti-target cell antibodies.The Journal of Experimental Medicine, 1986
- Regulation of immune response by antibodies: the importance of antibody and monocyte Fc receptor interaction in T-cell activationImmunology Today, 1985
- Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibodyNature, 1985
- Hybrid antibodies can target sites for attack by T cellsNature, 1985
- Immunotoxins: A New Approach to Cancer TherapyScience, 1983
- LIPOSOMALLY ENTRAPPED SECOND ANTIBODY IMPROVES TUMOUR IMAGING WITH RADIOLABELLED (FIRST) ANTITUMOUR ANTIBODYThe Lancet, 1982
- Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype AntibodyNew England Journal of Medicine, 1982
- Mitogenic actions of orthoclone OKT3 on human peripheral blood lymphocytes: Effects of monocytes and serum componentsInternational Journal of Immunopharmacology, 1981